CDC treats first mon­key­pox pa­tient with SIGA's small­pox an­tivi­ral via ex­pand­ed ac­cess

The CDC said Fri­day that one mon­key­pox pa­tient in the US so far has been treat­ed with SIGA Tech­nolo­gies’ tecovir­i­mat, known com­mer­cial­ly as TPOXX, which is an an­tivi­ral agent from the strate­gic na­tion­al stock­pile with an­ti-or­thopoxvirus ac­tiv­i­ty.

The an­tivi­ral is on­ly cur­rent­ly li­censed to treat small­pox, so the FDA and com­pa­ny made it avail­able to CDC un­der an ex­pand­ed ac­cess IND.

CDC al­so said it re­leased small­pox vac­cines — Emer­gent’s ACAM2000 and Bavar­i­an Nordic’s Jyn­neos — to those at high-risk of ex­po­sure to mon­key­pox, ei­ther through con­tact with some­one who has it, or cer­tain in­ter­me­di­ate risk ex­po­sures, such as be­ing with­in ≤6 feet of an un­masked pa­tient for ≥3 hours with­out wear­ing, at a min­i­mum, a sur­gi­cal mask.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.